TD Asset Management Inc Reduces Stake in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• TD Asset Management Inc decreased its stake in Ultragenyx Pharmaceutical Inc. by 10.5%, now holding approximately 123,884 shares worth $4,504,000 after selling 14,600 shares in the second quarter.
• Multiple institutional investors have modified their holdings in Ultragenyx, with GAMMA Investing LLC increasing its stake by 76.2% and Parallel Advisors LLC boosting theirs by 1,061.9%.
• Recent analyst ratings show a consensus of "Moderate Buy" for Ultragenyx, with a target price averaging around $82.27, despite some firms adjusting their targets downwards.

TD Asset Management Inc reduced its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 10.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 123,884 shares of the biopharmaceutical company's stock after selling 14,600 shares during the period. TD Asset Management Inc owned approximately 0.13% of Ultragenyx Pharmaceutical worth $4,504,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 669 shares during the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth $57,000. Headlands Technologies LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth $59,000. Finally, Covestor Ltd boosted its stake in shares of Ultragenyx Pharmaceutical by 86.8% in the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock worth $62,000 after buying an additional 795 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RARE has been the topic of a number of recent research reports. Wells Fargo & Company initiated coverage on Ultragenyx Pharmaceutical in a report on Monday. They issued an "overweight" rating and a $65.00 target price on the stock. Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Canaccord Genuity Group decreased their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $105.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th. Finally, Wedbush decreased their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday, July 14th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus target price of $82.27.

Ultragenyx Pharmaceutical Stock Up 5.4%

NASDAQ:RARE opened at $34.40 on Tuesday. The business's 50-day simple moving average is $30.35 and its two-hundred day simple moving average is $32.89. The stock has a market cap of $3.32 billion, a PE ratio of -6.22 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $56.38.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business's quarterly revenue was up 13.2% on a year-over-year basis. During the same period last year, the firm earned ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the firm's stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the sale, the chief financial officer directly owned 98,227 shares of the company's stock, valued at $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the sale, the executive vice president directly owned 73,271 shares in the company, valued at approximately $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,456 shares of company stock worth $328,486. Insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.